Core Insights - The company reported a revenue of 1.008 billion yuan for the first half of 2025, representing a year-on-year growth of 12.51% [1] - The net profit attributable to shareholders decreased to 225 million yuan, a decline of 28.68% compared to the previous year [1] - The basic earnings per share stood at 0.45 yuan [1] - The company plans to distribute a cash dividend of 1.5 yuan per 10 shares (tax included) [1] Financial Performance - Revenue for the first half of 2025: 1.008 billion yuan, up 12.51% year-on-year [1] - Net profit attributable to shareholders: 225 million yuan, down 28.68% year-on-year [1] - Basic earnings per share: 0.45 yuan [1] Dividend Announcement - Proposed cash dividend: 1.5 yuan per 10 shares (including tax) [1] Reasons for Profit Decline - The decline in net profit is primarily attributed to the decrease in gross profit from blood products and the amortization of the valuation increase resulting from the acquisition of Green Cross [1]
博雅生物：上半年净利润同比下降28.68% 拟10派1.5元